Last reviewed · How we verify
Mpox Vaccine
The Mpox vaccine stimulates the immune system to produce antibodies and cellular immunity against Mpox virus antigens, providing protection against infection.
The Mpox vaccine stimulates the immune system to produce antibodies and cellular immunity against Mpox virus antigens, providing protection against infection. Used for Prevention of Mpox (monkeypox) infection.
At a glance
| Generic name | Mpox Vaccine |
|---|---|
| Sponsor | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia |
| Drug class | vaccine |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Mpox vaccines work by introducing viral antigens (either live attenuated virus, recombinant proteins, or viral vectors) to train the adaptive immune system to recognize and respond to Mpox virus. This generates both humoral (antibody-mediated) and cell-mediated immune responses that prevent infection or reduce disease severity upon exposure to the virus.
Approved indications
- Prevention of Mpox (monkeypox) infection
Common side effects
- Injection site pain or erythema
- Fatigue
- Headache
- Myalgia
- Fever
Key clinical trials
- A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines (PHASE1, PHASE2)
- A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox (PHASE2)
- Prospective Study for the FOLLOW-UP of Human Monkeypox Cases and Smallpox Vaccinees at Risk
- A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa (PHASE2)
- Phase 3 Maternal Safety & Immunogenicity Trial of MVA-BN® in DRC (PHASE3)
- Evaluate the Safety and Immunogenicity of the MVA-SIBP Vaccine in the Democratic Republic of the Congo (PHASE2)
- Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections (PHASE2)
- New York City Observational Study of Mpox Immunity
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |